Filing scope and business context
The supplied filing is ChromaDex Corporation’s Form 10-K for the fiscal year ended December 31, 2023—not a filing identified as Niagen Bioscience, Inc. It reports full-year results, not a standalone 2023 fourth quarter. ChromaDex sells Tru Niagen consumer supplements and Niagen ingredients, and provides analytical reference standards and related services.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | $83.6 million | $72.1 million |
| Gross profit / margin | $50.8 million / 60.8% | $42.8 million / approximately 59.4% |
| Operating loss | $5.6 million | $18.6 million |
| Net loss | $4.9 million | $16.5 million |
| Basic and diluted loss per share | $0.07 | $0.24 |
| Cash provided by (used in) operating activities | $7.1 million | $(15.1) million |
- Sales increased 16%. Consumer Products revenue rose 16% to $69.5 million; Ingredients rose 27% to $11.1 million; Analytical Reference Standards and Services fell 9% to $2.9 million.
- Gross margin improved about 140 basis points. Lower sales and marketing expense and general and administrative expense also helped narrow the operating and net losses. 2022 included $2.1 million of Employee Retention Tax Credit income; 2023 did not.
- At year-end, cash and cash equivalents were $27.3 million, including $27.2 million unrestricted. Working capital, as defined by the company, was $9.5 million, down from $13.5 million.
- No line-of-credit borrowings were outstanding. The revolving facility provides up to $10.0 million, subject to terms and conditions, and matures November 2025. Total liabilities were $26.5 million and stockholders’ equity was $28.5 million.
- Inventory was $14.5 million; trade receivables were $5.2 million. Approximately 81% of receivables were concentrated among three customers. A.S. Watson, a related party, represented 15.4% of sales and 52.7% of year-end receivables.
Changes, outlook, risks and unusual items
- Management says current unrestricted cash and expected cash from sales should cover obligations for at least the next 12 months, while noting recurring losses, historical negative operating cash flow and inflationary pressures. It may seek additional capital for longer-term plans; no specific revenue or earnings guidance is provided.
- The company committed to approximately $15.9 million of inventory purchases during 2024. Niagen supply remains a key risk: W.R. Grace is the principal supplier, the supply agreement expires December 31, 2024, and renewal terms remain to be negotiated. A limited license permits specified third-party supply in 2024.
- Consumer Products growth benefited from e-commerce and higher A.S. Watson sales. Ingredients growth reflected stronger Niagen ingredient sales and new or expanded partnerships, partly offset by the absence of Nestlé’s 2022 upfront purchase. Analytical segment revenue weakened with lower reference-standard demand.
- ChromaDex remains involved in complex Elysium litigation. The filing describes a California action with claims and counterclaims still requiring further proceedings; outcomes and potential financial exposure are uncertain. In a separate patent case, courts upheld invalidation of the Dartmouth patents at issue, and the Supreme Court denied review in October 2023. The company said that decision is not expected to materially affect its NR business.
- China expansion depends on “Blue Hat” registration; achievement and timing were uncertain at year-end, and joint venture activity was not material in 2023. A $1.0 million registration fee and related equity compensation depend on registration.
- The company recorded a $964,000 provision for doubtful receivables, primarily related to ShopHQ owner iMedia Brands’ Chapter 11 filing, and wrote off the full provision. The remaining $0.9 million ERTC benefit receivable is subject to IRS processing and increased compliance scrutiny.
- Other principal risks include dependence on Tru Niagen and a major customer, supplement regulation and consumer perceptions, competition, supplier concentration, litigation, and the potential need for financing. Management reported effective disclosure controls and internal control over financial reporting; the auditor gave an unqualified opinion on the financial statements and reported no critical audit matters.
Important facts for investors to verify
- Confirm the issuer: the filing is for ChromaDex Corporation (CDXC), despite the request metadata naming Niagen Bioscience, Inc.
- Track cash generation and progress toward sustained profitability, including the working-capital drivers behind 2023 operating cash flow.
- Monitor Grace contract renewal, the 2024 inventory commitment, and any evidence of reliable alternative NR supply.
- Review receivable collections and exposure to A.S. Watson and other major customers, plus the status of the iMedia/ShopHQ write-off and ERTC claim.
- Follow Elysium litigation developments, China registration progress, and any financing or dilution needs.